Literature DB >> 28116452

Understanding therapeutic targets in thrombotic thrombocytopenic purpura.

Bérangère S Joly1, Karen Vanhoorelbeke2, Agnès Veyradier3.   

Abstract

Entities:  

Keywords:  ADAMTS13 Deficiency; Eculizumab; High Molecular Weight Multimers; Thrombotic Thrombocytopenic Purpura; Thrombotic Thrombocytopenic Purpura Patient

Mesh：

Substances：

Year:  2017        PMID： 28116452     DOI： 10.1007/s00134-016-4662-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  18 in total

Review 1.  Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.

Authors:  James N George
Journal:  Am J Hematol       Date:  2012-03-09       Impact factor: 10.047

Review 2.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

3.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

4.  Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.

Authors:  Petra Jilma-Stohlawetz; Monika E Gorczyca; Bernd Jilma; Jolanta Siller-Matula; James C Gilbert; Paul Knöbl
Journal:  Thromb Haemost       Date:  2010-12-21       Impact factor: 5.249

5.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Flora Peyvandi; Marie Scully; Johanna A Kremer Hovinga; Spero Cataland; Paul Knöbl; Haifeng Wu; Andrea Artoni; John-Paul Westwood; Magnus Mansouri Taleghani; Bernd Jilma; Filip Callewaert; Hans Ulrichts; Christian Duby; Dominique Tersago
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

6.  Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.

Authors:  B Plaimauer; J A Kremer Hovinga; C Juno; M J Wolfsegger; S Skalicky; M Schmidt; L Grillberger; M Hasslacher; P Knöbl; H Ehrlich; F Scheiflinger
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

7.  Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.

Authors:  Bérangère S Joly; Alain Stepanian; Thierry Leblanc; David Hajage; Hervé Chambost; Jérôme Harambat; Fanny Fouyssac; Vincent Guigonis; Guy Leverger; Tim Ulinski; Thérésa Kwon; Chantal Loirat; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-10-03       Impact factor: 18.959

8.  Recombinant ADAMTS 13 Attenuates Brain Injury After Intracerebral Hemorrhage.

Authors:  Ping Cai; Haiyu Luo; Haochen Xu; Ximin Zhu; Wenfang Xu; Yiqin Dai; Jin Xiao; Yongliang Cao; Yuwu Zhao; Bing-Qiao Zhao; Wenying Fan
Journal:  Stroke       Date:  2015-08-06       Impact factor: 7.914

9.  Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.

Authors:  Eric Mariotte; Elie Azoulay; Lionel Galicier; Eric Rondeau; Fouzia Zouiti; Pierre Boisseau; Pascale Poullin; Emmanuel de Maistre; François Provôt; Yahsou Delmas; Pierre Perez; Ygal Benhamou; Alain Stepanian; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-04-16       Impact factor: 18.959

10.  What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015
View more
  2 in total

Review 1.  Understanding thrombotic microangiopathies in children.

Authors:  Bérangère S Joly; X Long Zheng; Agnès Veyradier
Journal:  Intensive Care Med       Date:  2018-01-24       Impact factor: 17.440

2.  A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis.

Authors:  Agnès Veyradier
Journal:  Haematologica       Date:  2020-11-01       Impact factor: 9.941
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.